PHR trades 11.0% below Wall Street's consensus target of $12.14.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PHR achieves its forward estimates and maintains a stable P/E multiple of 36.6x. This scenario reflects the blended consensus of 26 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 17, 2026, Phreesia, Inc. (PHR) has a Wall Street consensus price target of $12.14, based on estimates from 26 covering analysts. With the stock currently trading at $10.94, this represents a potential upside of +11.0%. The company has a market capitalization of $676M.
Analyst price targets range from a low of $10.00 to a high of $16.00, representing a 49% spread in expectations. The median target of $12.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PHR trades at a trailing P/E of 291.7x and forward P/E of 36.6x. Analysts expect EPS to grow +78.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HCATHealth Catalyst, Inc. | $128M | $1.73 | $1.77 | +2.6% | Buy | — | 22 |
 DOCSDoximity, Inc. | $5.8B | $30.97 | $27.73 | -10.5% | Hold | 23.0x | 24 |
 GDRXGoodRx Holdings, Inc. | $1.2B | $3.36 | $4.19 | +24.7% | Hold | 11.1x | 24 |
 VEEVVeeva Systems Inc. | $50.4B | $310.36 | $291.75 | -6.0% | Buy | 33.6x | 43 |
 INVAInnoviva, Inc. | $1.5B | $20.78 | $38.00 | +82.9% | Buy | 8.6x | 10 |
 TDOCTeladoc Health, Inc. | $1.0B | $5.67 | $8.83 | +55.7% | Hold | — | 42 |
 AMWLAmerican Well Corporation | $199M | $11.68 | $13.00 | +11.3% | Hold | — | 15 |
 PGNYProgyny, Inc. | $2.1B | $26.86 | $35.50 | +32.2% | Buy | 20.9x | 20 |
 CLOVClover Health Investments, Corp. | $2.3B | $4.48 | $5.50 | +22.8% | Hold | 80.0x | 9 |
 LFSTLifeStance Health Group, Inc. | $4.6B | $11.74 | $14.14 | +20.4% | Buy | 73.1x | 11 |
Quick answers to the most common questions about buying PHR stock.
Phreesia, Inc. (PHR) has a consensus 12-month price target of $12.14, implying 11.0% upside from $10.94. The 26 analysts covering PHR see moderate appreciation potential.
PHR has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $12.14 implies 11.0% upside from current levels.
At a forward P/E of 36.5764x, PHR trades at a premium valuation. The consensus price target of $12.14 (11.0% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $16 for PHR, while the most conservative target is $10. The consensus of $12.14 represents the median expectation. These targets typically reflect 12-month expectations.
PHR is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 8 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PHR stock forecast based on 26 Wall Street analysts shows a consensus price target of $12.14, with estimates ranging from $10 (bear case) to $16 (bull case). The median consensus rating is "Buy".
PHR trades at a forward P/E ratio of 36.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 291.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on PHR, with a "Buy" consensus rating and $12.14 price target (11.0% upside). 18 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PHR analyst price targets range from $10 to $16, a 49% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12.14 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.